極光激酶是維持細(xì)胞基因組完整性的關(guān)鍵絲氨酸/蘇氨酸有絲分裂調(diào)節(jié)激酶，由3個(gè)成員極光激酶A、B、C組成，其中極光激酶B在有絲分裂中起著至關(guān)重要的作用。極光激酶B在多種惡性腫瘤中過表達(dá)，故極光激酶B被作為有吸引力的抗癌藥物靶點(diǎn)被廣泛研究，目前已經(jīng)開發(fā)了多種靶向極光激酶B的小分子抑制劑。介紹了極光激酶B特異性抑制劑、進(jìn)入臨床試驗(yàn)階段的泛極光激酶抑制劑等的研究進(jìn)展，希望為極光激酶B抑制劑的開發(fā)和臨床使用提供參考。

Aurora kinase is a key serine/threonine mitotic regulatory kinase that maintains the integrity of the cell genome, consisting of three members, aurora kinases A, B, and C. Aurora kinase B plays a crucial role in mitosis. Over-expression of aurora kinase B is frequently observed in various malignant tumors, so aurora kinase B has been widely studied as an attractive anticancer drug target. Currently, various small molecule inhibitors targeting aurora kinase B have been developed. This article introduces the research progress of aurora kinase B specific inhibitors and pan-aurora kinase inhibitors entering the clinical trial stage, hoping to provide reference for the development and clinical use of aurora kinase B inhibitors.

R961

甘肅省自然科學(xué)基金資助項(xiàng)目(22JR5RA021)